{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T02:04:35Z","timestamp":1788401075410,"version":"build-2803163510"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,5,15]]},"DOI":"10.2146\/ajhp130483","type":"journal-article","created":{"date-parts":[[2014,4,29]],"date-time":"2014-04-29T13:41:56Z","timestamp":1398778916000},"page":"793-798","source":"Crossref","is-referenced-by-count":15,"title":["Glucarpidase for the management of elevated methotrexate levels in patients with impaired renal function"],"prefix":"10.1093","volume":"71","author":[{"given":"Mariana","family":"Fermiano","sequence":"first","affiliation":[{"name":"State University of Campinas, Sao Paulo, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Bergsbaken","sequence":"additional","affiliation":[{"name":"University of Wisconsin (UW) Hospital and Clinics, Madison."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill M.","family":"Kolesar","sequence":"additional","affiliation":[{"name":"State University of Campinas, Sao Paulo, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"2019041211004480700_b1-0710793","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/CAD.0b013e32835b8662","article-title":"Comparison of pharmacokinetics and toxicity after high-dose methotrexate treatments in children with acute lymphoblastic leukemia","volume":"24","author":"Csordas","year":"2013","journal-title":"Anticancer Drugs"},{"key":"2019041211004480700_b2-0710793","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2147\/TCRM.S30135","article-title":"Glucarpidase to combat toxic levels of methotrexate in patients","volume":"8","author":"Green","year":"2012","journal-title":"Ther Clin Risk Manag"},{"key":"2019041211004480700_b3-0710793","unstructured":"LaCasce AS, for UpToDate, Inc. Therapeutic use and toxicity of high-dose methotrexate. www.uptodate.com\/contents\/therapeutic-use-and-toxicity-of-high-dose-methotrexate (accessed 2014 Feb 12)."},{"key":"2019041211004480700_b4-0710793","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1634\/theoncologist.12-11-1299","article-title":"Glucarpidase (carboxypeptidase g2) intervention in adult and elderly cancer patients with renal dysfunction and delayed methotrexate elimination after high-dose methotrexate therapy","volume":"12","author":"Schwartz","year":"2007","journal-title":"Oncologist"},{"key":"2019041211004480700_b5-0710793","volume-title":"Voraxaze (glucarpidase) prescribing information","year":"2012"},{"key":"2019041211004480700_b6-0710793","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1002\/cncr.20255","article-title":"High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma","volume":"100","author":"Widemann","year":"2004","journal-title":"Cancer"},{"key":"2019041211004480700_b7-0710793","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1634\/theoncologist.11-6-694","article-title":"Understanding and managing methotrexate nephrotoxicity","volume":"11","author":"Widemann","year":"2006","journal-title":"Oncologist"},{"key":"2019041211004480700_b8-0710793","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1200\/JCO.2009.25.4540","article-title":"Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome","volume":"28","author":"Widemann","year":"2010","journal-title":"J Clin Oncol"},{"key":"2019041211004480700_b9-0710793","doi-asserted-by":"crossref","first-page":"4321","DOI":"10.1002\/cncr.27378","article-title":"Resumption of high-dose methotrexate after acute kidney injury and glucarpidase use in pediatric oncology patients","volume":"118","author":"Christensen","year":"2012","journal-title":"Cancer"},{"key":"2019041211004480700_b10-0710793","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1177\/0091270007311571","article-title":"Pharmacokinetics of glucarpidase in subjects with normal and impaired renal function","volume":"48","author":"Phillips","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"2019041211004480700_b11-0710793","first-page":"106","article-title":"Prevention and management of high dose methotrexate toxicity","volume":"5","author":"Ahmed","year":"2013","journal-title":"J Cancer Sci Ther"},{"key":"2019041211004480700_b12-0710793","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/00007691-198603000-00020","article-title":"Evaluation of a fluorescence polarization immunoassay procedure for quantitation of methotrexate","volume":"8","author":"Pesce","year":"1986","journal-title":"Ther Drug Monit"},{"key":"2019041211004480700_b13-0710793","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1373\/clinchem.2010.144824","article-title":"Difficulty measuring methotrexate in a patient with high-dose methotrexate-induced nephrotoxicity","volume":"56","author":"Al-Turkmani","year":"2010","journal-title":"Clin Chem"},{"key":"2019041211004480700_b14-0710793","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/sj.bjc.6602337","article-title":"Carboxypeptidase G2 rescue in patients with methotrexate intoxication and renal failure","volume":"92","author":"Buchen","year":"2005","journal-title":"Br J Cancer"},{"key":"2019041211004480700_b15-0710793","article-title":"Efficacy of glucarpidase (carboxypeptidase G2) in patients with acute kidney injury after high-dose methotrexate therapy","author":"Widemann","year":"2013","journal-title":"Pharmacotherapy"},{"key":"2019041211004480700_b16-0710793","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1093\/jnci\/djh270","article-title":"Treatment of accidental intrathecal methotrexate overdose with intrathecal carboxypeptidase G2","volume":"96","author":"Widemann","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"2019041211004480700_b17-0710793","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1200\/JCO.1991.9.4.670","article-title":"Rescue of experimental intrathecal methotrexate overdose with carboxypeptidase-G2","volume":"9","author":"Adamson","year":"1991","journal-title":"J Clin Oncol"},{"key":"2019041211004480700_b18-0710793","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.2146\/news120070","article-title":"CMS to compensate hospitals for inpatient use of fidaxomicin, glucarpidase","volume":"69","author":"Thompson","year":"2012","journal-title":"Am J Health-Syst Pharm"},{"key":"2019041211004480700_b19-0710793","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1523-1755.2005.00413.x","article-title":"Impact of initial dialysis modality and modality switches on Medicare expenditures of end-stage renal disease patients","volume":"68","author":"Shih","year":"2005","journal-title":"Kidney Int"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/71\/10\/793\/28372605\/ajhp0793.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,13]],"date-time":"2019-04-13T00:48:32Z","timestamp":1555116512000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/71\/10\/793\/5110885"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,15]]},"references-count":19,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,5,15]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp130483","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2014,5,15]]},"published":{"date-parts":[[2014,5,15]]}}}